Alpine Associates Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Alpine Associates Management’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,016,700	Closed	-$19.4M	–	65
2024 Q4	$19.4M	Buy	+2,016,700	New	+$10.5M	1.17%	27

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Alpine Associates Management's PSTX Position: Q1 2025 in Review

Alpine Associates Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 2,016,700 shares — an estimated $19.4M sold.

Alpine Associates Management first reported a position in PSTX in Q4 2024 and held it in 1 quarter. The position peaked at $19.4M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

Alpine Associates Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Alpine Associates Management sold 2,016,700 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $19.4M.
Alpine Associates Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2024 and held it in 1 quarter.
Alpine Associates Management's Poseida Therapeutics, Inc. Common Stock position peaked at $19.4M in Q4 2024.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Alpine Associates Management's 13F filing for Q1 2025, filed 8 May 2025.